Sangamo Therapeutics, Inc. (SGMOQ)
0.1475
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Sangamo Therapeutics Net Income (Quarterly) : -31.00M for March 31, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -31.00M |
| December 31, 2025 | -37.42M |
| September 30, 2025 | -34.93M |
| June 30, 2025 | -19.99M |
| March 31, 2025 | -30.60M |
| December 31, 2024 | -23.40M |
| September 30, 2024 | 9.385M |
| June 30, 2024 | -36.13M |
| March 31, 2024 | -49.09M |
| December 31, 2023 | -60.30M |
| September 30, 2023 | -104.16M |
| June 30, 2023 | -114.51M |
| March 31, 2023 | 21.13M |
| December 31, 2022 | -51.97M |
| September 30, 2022 | -53.16M |
| June 30, 2022 | -43.17M |
| March 31, 2022 | -43.98M |
| December 31, 2021 | -37.50M |
| September 30, 2021 | -47.69M |
| June 30, 2021 | -47.17M |
| March 31, 2021 | -45.94M |
| December 31, 2020 | -40.68M |
| September 30, 2020 | -1.508M |
| June 30, 2020 | -35.96M |
| March 31, 2020 | -42.97M |
| Date | Value |
|---|---|
| December 31, 2019 | 4.501M |
| September 30, 2019 | -27.36M |
| June 30, 2019 | -30.36M |
| March 31, 2019 | -42.20M |
| December 31, 2018 | -19.22M |
| September 30, 2018 | -12.84M |
| June 30, 2018 | -16.64M |
| March 31, 2018 | -20.19M |
| December 31, 2017 | -13.09M |
| September 30, 2017 | -12.35M |
| June 30, 2017 | -12.49M |
| March 31, 2017 | -16.63M |
| December 31, 2016 | -9.624M |
| September 30, 2016 | -18.96M |
| June 30, 2016 | -26.58M |
| March 31, 2016 | -16.49M |
| December 31, 2015 | -14.01M |
| September 30, 2015 | -9.245M |
| June 30, 2015 | -12.13M |
| March 31, 2015 | -5.319M |
| December 31, 2014 | -4.319M |
| September 30, 2014 | -7.545M |
| June 30, 2014 | -6.981M |
| March 31, 2014 | -7.572M |
| December 31, 2013 | -8.144M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
| Vicapsys Life Sciences, Inc. | -0.1046M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 32.44M |
| EPS Diluted (Quarterly) | -0.0796 |
| Enterprise Value | 52.85M |
| Gross Profit Margin (Quarterly) | 39.18% |
| Profit Margin (Quarterly) | -2.15K% |
| Earnings Yield | -259.7% |
| Normalized Earnings Yield | -241.90 |